液体活检,肿瘤学的范式转变:介入放射科医生应了解的内容
本文为综述,阐述液体活检作为非侵入性替代组织采样的技术,通过采集血液或其他体液中的循环肿瘤DNA、循环肿瘤细胞及循环RNA(尤其microRNA)用于肿瘤筛查、复发检测和获得性耐药评估。文章指出介入放射学可通过直接采样肿瘤周围或引流液体提高液体活检敏感性,液体活检也可能帮助筛选适合图像引导局部区域治疗的患者、确定治疗终点和早期检出复发。
要点
- 液体活检通过血液或其他体液采集循环肿瘤DNA、循环肿瘤细胞和循环RNA(尤其microRNA)。
- 图像引导活检采样产量提高、患者风险降低,但仍具侵入性且不利于纵向肿瘤监测。
- 介入放射学可直接采样肿瘤周围或引流液体,可能提高液体活检敏感性。
核心结论
- 液体活检是肿瘤患者管理中的新技术,可能在接受图像引导操作的患者管理中具有高影响力。
- 介入放射学操作可通过直接液体采样提高液体活检敏感性。
- 液体活检技术可能为改进患者选择和改善介入放射科医生实施的局部区域治疗结局提供途径。
研究设计与样本
- 本文为综述,未报告系统检索范围与纳入文献数量。
诊断标准与关键数值
- 液体活检通过直接采样血液或其他与肿瘤接触的体液,收集循环肿瘤DNA、循环肿瘤细胞和循环RNA(尤其microRNA)。
- 液体活检临床应用涉及肿瘤患者管理的不同步骤,包括筛查、疾病复发检测和获得性耐药评估。
临床应用与阅片要点
- 介入放射学可能对直接采样肿瘤周围或引流液体具有整合作用。
- 液体活检可能帮助正确选择患者进行图像引导局部区域治疗、确定其治疗终点并早期检测复发。
局限性
- 图像引导活检仍具侵入性,并因此限制纵向肿瘤监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
The acquisition of adequate tumor sample is required to verify primary tumor type and specific biomarkers and to assess response to therapy. Historically, invasive surgical procedures were the standard methods to acquire tumor samples until advancements in imaging and minimally invasive equipment facilitated the paradigm shift image-guided biopsy. Image-guided biopsy has improved sampling yield and minimized risk to the patient; however, there are still limitations, such as its invasive nature and its consequent limitations to longitudinal tumor monitoring. The next paradigm shift in sampling technique will need to address these issues to provide a more reliable and less invasive technique. Recently, liquid biopsy (LB) has emerged as a non-invasive alternative to tissue sampling. This technique relies on direct sampling of blood or other bodily fluids in contact with the tumor in order to collect circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and circulating RNAs-in particular microRNA (miRNAs). Clinical applications of LB involve different steps of cancer patient management including screening, detection of disease recurrence, and evaluation of acquired resistance. With any paradigm shift, old techniques are often relegated to a secondary option. Although image-guided biopsies may appear as a passive spectator on the rapid advancement of LB, the two techniques may well be codependent. Interventional radiology may be integral to directly sample the liquid surrounding or draining from the tumor. In addition, LB may help to correctly select the patients for image-guided loco-regional treatments, to determine its treatment endpoint, and to early detect recurrence. KEY POINTS: • Liquid biopsy is a novel technology with potential high impact in the management of patients undergoing image-guided procedures. • Interventional radiology procedures may increase liquid biopsy sensitivity through direct fluid sampling. • Liquid biopsy techniques may provide a venue for improving patients' selection and enhance outcomes of interventional loco-regional therapies performed by interventional radiologists.
引用
- Calandri M, Siravegna G, Yevich SM, et al. Liquid biopsy, a paradigm shift in oncology: what interventional radiologists should know. Eur Radiol. 2020. PMID: 32193642. doi:10.1007/s00330-020-06700-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。